每经AI快讯，9月30日，南新制药(688189.SH)公告称，公司近日收到中国证监会出具的《立案告知 书》，因公司涉嫌年报信息披露违法违规，中国证监会决定对公司立案。立案调查期间，公司将积极配 合中国证监会的调查工作，并严格按照相关法律法规及监管要求及时履行信息披露义务。 ...

南新制药公告，公司于2025年8月27日披露了筹划重大资产重组事项，拟以现金方式收购未来医药持有 的标的资产组。然而，因未能就交易的核心条款达成一致意见，公司决定终止筹划本次交易。此次终止 不会对公司业务开展、生产经营活动和财务状况造成不利影响。公司承诺自公告之日起1个月内不再筹 划重大资产重组事项。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 ● 风险提示 本次交易尚处于筹划阶段，交易各方就交易事项仍在商讨，目前就交易核心条款还存在较大分歧，本次 交易存在不确定性。 截至本公告披露之日，公司及相关方正商讨论证本次交易的可行性，就交易核心条款还存在较大分歧， 本次交易存在不确定性。公司将继续按照《上市公司重大资产重组管理办法》及其他相关规定，及时履 行信息披露义务。 三、风险提示 本次交易尚处于筹划阶段，交易各方就交易事项仍在商讨，目前就交易核心条款还存在较大分歧，本次 交易存在不确定性。 本次交易需按照相关法律、法规及公司章程的规定履行必要的决策和审批程序，最终能否实施存在不确 定性。 公司指定信息披露媒体为《上海证券报》、《中国证券报》、《证券时报》、《证券日报》及上海证券 交易所网站（www.sse.com.cn），有关公司的信息均以在上述指定信息披露媒体刊登的公告信息为准。 公司将根据相关事项的进展情况及时履行信息披露义务。 敬请广大投资者理性投资，注意投资风 ...

证券代码：688189 证券简称：南新制药 公告编号：2025-042 湖南南新制药股份有限公司 关于筹划重大资产重组事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 风险提示 本次交易尚处于筹划阶段，交易各方就交易事项仍在商讨，目前就交易核心 条款还存在较大分歧，本次交易存在不确定性。 本次交易需按照相关法律、法规及公司章程的规定履行必要的决策和审批程 序，最终能否实施存在不确定性。敬请广大投资者理性投资，注意投资风险。 一、本次筹划重大资产重组事项的基本情况 截至本公告披露之日，公司及相关方正商讨论证本次交易的可行性，就交易 核心条款还存在较大分歧，本次交易存在不确定性。公司将继续按照《上市公司 重大资产重组管理办法》及其他相关规定，及时履行信息披露义务。 三、风险提示 本次交易尚处于筹划阶段，交易各方就交易事项仍在商讨，目前就交易核心 条款还存在较大分歧，本次交易存在不确定性。 本次交易需按照相关法律、法规及公司章程的规定履行必要的决策和审批程 序，最终能否实施存在不确定性。 公司指定信息披露媒体为《上 ...

南新制药公告，2025年8月26日，湖南南新制药股份有限公司与西藏未来生物医药股份有限公司、许昌 未来制药有限责任公司和合肥市未来药物开发有限公司签署《收购意向协议》，公司拟以现金方式收购 未来医药持有的标的资产组。本次交易尚处于筹划阶段，交易各方就交易事项仍在商讨，目前就交易核 心条款还存在较大分歧，本次交易存在不确定性。 ...

Group 1 - Shengke Communication's shareholding by the National Integrated Circuit Industry Investment Fund has decreased from 19.6% to 15% after a total reduction of 18.8569 million shares [1] - Guoxin Technology plans to reduce its shares by up to 4.5% through various trading methods between September 30, 2025, and December 29, 2025 [1][2] - Jingzhida has delivered its first high-speed testing machine to a key domestic customer, aimed at semiconductor memory testing [4][5] Group 2 - Nanxin Pharmaceutical's shareholder plans to reduce shares by up to 3%, totaling 823.2 million shares, due to funding needs [6] - *ST Taihe's shareholder intends to reduce shares by up to 3% for operational management needs [7] - Xincheng Technology's shareholders and directors plan to reduce shares by up to 2.03% due to personal funding needs [8] Group 3 - Huati Technology is planning to acquire shares of Huayi Microelectronics, leading to a stock suspension due to uncertainties [9] - Ruima Precision's subsidiary has received a project notification with a total lifecycle sales estimate of approximately 5.56 billion yuan [10] - Guoguang Electric's shareholders plan to reduce shares by up to 3.85% through various trading methods [10] Group 4 - Cangge Mining's shareholder plans to reduce shares by up to 0.6% due to funding needs [11] - Jujiao Co., Ltd. intends to reduce shares by up to 3% due to personal funding arrangements [12] - Maqu'er plans to reduce shares by up to 2% due to funding needs [13] Group 5 - Caesar Travel's subsidiary intends to acquire 100% equity of Qingdao Hansa for 16 million yuan [14] - Xinde New Materials' shareholders plan to reduce shares by up to 3% through various trading methods [15] - Huadong Heavy Machinery's shareholders plan to reduce shares by up to 1.5% [16] Group 6 - Zhejiang Zhongcheng's shareholder plans to reduce shares by up to 3% due to personal funding needs [17] - Huaxi Securities' shareholder plans to reduce shares by up to 1% due to liquidity needs [18] - Ameng Pharmaceutical's major shareholder opposes the introduction of a strategic investor due to concerns over financial strength and compliance [19] Group 7 - *ST Rindong plans to invest 100 million yuan in Jiangyuan Technology, with a post-investment shareholding of 4.14% [20][21] - International Industry plans to issue shares to its controlling shareholder to raise no more than 662 million yuan for working capital [22][23]

Core Viewpoint - Guangzhou Qianyuan Investment Consulting Partnership plans to reduce its stake in Nanxin Pharmaceutical due to funding needs, with a total reduction not exceeding 8,232,000 shares, representing 3.00% of the company's total share capital [1][2]. Group 1: Share Reduction Plan - The reduction will occur through centralized bidding and block trading within three months after the announcement, starting from 15 trading days post-announcement [1]. - The maximum number of shares to be reduced via centralized bidding is 2,744,000 shares, with a limit of 1% of the total share capital within any consecutive 90-day period [1]. - The maximum number of shares to be reduced via block trading is 5,488,000 shares, with a limit of 2% of the total share capital within any consecutive 90-day period [1]. Group 2: Shareholder Information - As of the announcement date, Guangzhou Qianyuan holds 43,120,000 shares, accounting for 15.71% of the total share capital [2]. - The shares held include 22,000,000 shares acquired before the IPO, 8,800,000 shares from capital reserve conversion in 2021, and 12,320,000 shares from capital reserve conversion in 2022 [2]. Group 3: Company Background - Nanxin Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 26, 2020, with an initial offering price of 34.94 yuan per share [3]. - The total funds raised from the IPO amounted to 1.223 billion yuan, with a net amount of 1.135 billion yuan, exceeding the original target by 466 million yuan [3]. - The company incurred total issuance costs of 87.6177 million yuan, with underwriting fees to the lead underwriter, Western Securities, totaling 71.1075 million yuan [3].

| 股东名序 | ["州蛇元投资咨询合伙企业有限合伙) | | | --- | --- | --- | | | 中世反失、安全人及一致行动人 H CHE START FOR F | ■NV & | | 股东身份. | 童事、三事和高级管理人员 11-10 1/5 1/1 | DEVE | | ass Roll | 43,120,000 12 | | | 持設比例 | :15,71% | | | 当前持股股份来源 | IPO # W : 22,000,000 2 : 000 托电方式(1):21.120,000 2 | | | 股东名房 | "州乾元投资营询合伙企业(有限合伙) | | --- | --- | | 计划成特數量 | 个图:8.232.000 股 | | 计划成排出例 | 个粒过:3.00% | | 城持方式及对应减持数据 | 繁中臣价藏持,不超过:2744.000 > 大元文物流行,个相对:5.488,000 2 | | 成持期间 | 2025 = 10 = 27 - 2026 = 1 月26日 | | 机减排设计来源 | IPO之前取得,资本公积金转载设备取得 | | 那成特别更 | 资金需求 ...

（编辑 任世碧） 证券日报网讯 9月24日晚间，南新制药发布公告称，至本公告披露日，公司股东广州乾元投资咨询合伙 企业（有限合伙）（简称"广州乾元"）持有公司股份43，120，000股，占公司总股本的15.71%。因资金 需求，广州乾元拟通过集中竞价交易和大宗交易方式减持其所持有的公司股份，在本减持计划披露之日 起十五个交易日后的三个月内进行，合计减持股份数量不超过8，232，000股，不超过公司总股本的 3.00%。其中，采取集中竞价交易方式减持公司股份的，减持数量不超过2，744，000股，且任意连续 90日内减持股份总数不超过公司总股本的1%；采取大宗交易方式减持公司股份的，减持数量不超过5， 488，000股，且任意连续90日内减持股份总数不超过公司总股本的2%。 ...

南新制药(688189.SH)发布公告，因资金需求，广州乾元拟通过集中竞价交易和大宗交易方式减持其所 持有的公司股份，在本减持计划披露之日起十五个交易日后的三个月内进行，合计减持股份数量不超过 823.2万股，不超过公司总股本的3%。 ...